ProCE Banner Activity

Idelalisib ± Bendamustine/Rituximab in Relapsed/Refractory CLL

Slideset Download
Conference Coverage
Combination idelalisib plus BR therapy significantly improved survival outcomes in patients with R/R CLL.

Released: December 17, 2015

Expiration: December 15, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen